Our study clearly demonstrated the clinical perspective regarding sequential treatments with first-line bevacizumab combined with 1st/2nd-generation EGFR-TKIs in advanced lung adenocarcinoma patients harboring EGFR mutations. The gene discussed is EGFR; the disease is lung adenocarcinoma.